Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | XXII 0.1977 -8.34% | SHFS 0.1324 -61.39% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | YFOR 0.2236 -1.58% | RBNE 0.19 -2.56% | TQQQ 66.29 -0.20% | VZ 44.66 -1.19% | TSLL 9.76 -1.21% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | SQQQ 39.68 0.20% | AIOK 12.02 182.82% | ONDS 6.2 2.99% | AAPL 347.725 -0.14% | LABT 0.31 -36.67% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | GRAB 2.79 -2.11% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | IREN 24.905 -2.37% | QID 14.55 0.14% | RKT 11.73 -0.09% | WULF 11.32 0.00% | BE 193.3 -11.24%
CECertara, Inc. logo

Certara, Inc. (CERT)

NASDAQ Global Select · Currency in USD
$10.33 ▲ +0.24 (+2.38%)
At close: Oct 23, 4:00 PM ET. Market closed.
$10.44 ▲ +0.11 (+1.06%)
After hours: Oct 23, 7:30 PM ET

Summary

Previous Close
$10.09
Open
$9.84
Day's Range
$9.84 – $10.34
52 Week Range
$4.45 – $12.94
Volume
2,058,145
Avg. Volume
3,413,561
Market Cap
$1.58B
Beta (5Y Monthly)
1.43
PE Ratio (TTM)
--
EPS (TTM)
-$0.44
Earnings Date
Nov 5, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$8.50

Profile: Certara, Inc.

Sector
Healthcare
Industry
Medical - Healthcare Information Services
Full-time employees
1,546
CEO
Jon Resnick

Certara, Inc. provides advanced software solutions and technology-driven services, specializing in biosimulation throughout the entire drug development lifecycle. From initial drug discovery and preclinical research to clinical trials, regulatory submissions, and market entry, the company's core mission is to accelerate the delivery of new medicines to patients by transforming these processes with its innovative biosimulation software and expertise. Its extensive portfolio of technology-enabled services includes mechanistic and empirical biosimulation, strategic guidance for drug development and regulatory affairs, clinical pharmacology, model-based meta-analysis, specialized regulatory writing and medical communications, regulatory operations support, and market access consultation.

Earnings

Next report: Thu, Nov 5, 2026
EPS estimate $0.09 · Revenue est. $91.93M
DateEst.Actual
Aug 4, 2026$0.09$0.08Miss
May 11, 2026$0.11$0.09Miss
Feb 26, 2026$0.11$0.09Miss
Nov 6, 2025$0.11$0.14Beat
Aug 6, 2025$0.10$0.07Miss
May 5, 2025$0.13$0.14Beat

Analyst view

Consensus price target
$8.50 ▼ -17.7%
Range $7.50 – $10.00
Rating: Hold
Buy 47% · Hold 53% · Sell 0%

Similar stocks

Get free alerts on CERT and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.